7 withdrawn. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Withdrawn 7 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Metabolic treatment - Cancer, Overall Survival | Phase 3 | Withdrawn | Health Clinics Limited | 2022-05-23 | 2022-07-18 | |
| A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis CV-MG01, Placebo - Myasthenia Gravis, Generalized | Phase 2 / Phase 3 | Withdrawn | CuraVac | 2018-07-01 | 2018-05-30 | |
| Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Temozolomide, ANP Therapy - Optic Nerve Glioma | Phase 3 | Withdrawn | Burzynski Research Institute | 2011-12-01 | 2017-07-26 | |
| Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases surgery, radiosurgery - Metastases, Cancer | Phase 3 | Withdrawn | Barretos Cancer Hospital | 2010-07-01 | 2014-02-04 | |
| XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema hCRF, placebo hCRF - Brain Edema, Brain Tumor | Phase 3 | Withdrawn | Celtic Pharma Development Services | 120 | 2006-01-01 | 2008-01-03 |
| Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme TransMID™ - Glioblastoma Multiforme | Phase 3 | Withdrawn | Xenova Biomedix | 323 | 2004-05-01 | 2009-01-07 |
| Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Isotretinoin, Procarbazine Hydrochloride - Brain and Central Nervous System Tumors | Phase 3 | Withdrawn | M.D. Anderson Cancer Center | 2012-02-22 |
Brain Neoplasms (5) · Astrocytoma (2) · Glioblastoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Brain Edema (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Edema (1) · Glioma (1) · Gliosarcoma (1) · Myasthenia Gravis (1) · Oligodendroglioma (1) · Optic Nerve Glioma (1)
Neoplasms by Site (7) · Nervous System Diseases (7) · Brain Diseases (5) · Central Nervous System Diseases (5) · Neoplasms (5) · Central Nervous System Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neoplasms, Neuroepithelial (4) · Neuroectodermal Tumors (4) · Pathological Conditions, Signs and Symptoms (4) · Glioma (3)
Atorvastatin (1) · Corticotropin-Releasing Hormone (1) · Doxycycline (1) · Isotretinoin (1) · Mebendazole (1) · Metformin (1) · Neurosurgical Procedures (1) · Procarbazine (1) · Radiosurgery (1) · Surgical Procedures, Operative (1) · Temozolomide (1) · Tf-CRM107 (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1)
Barretos Cancer Hospital (1) · Burzynski Research Institute (1) · Celtic Pharma Development Services (1) · CuraVac (1) · Health Clinics Limited (1) · M.D. Anderson Cancer Center (1) · Xenova Biomedix (1)
United States (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · United Kingdom (1)
Kurt A. Jaeckle, MD (1) · Ricardo A Nakamura, MD (1) · Rudy Mercelis, MD, PhD (1) · Samir Agrawal, MRCP FRCPath (1) · Stanislaw R Burzynski, MD, PhD (1) · William Shapiro, MD (1)
2017 (1), P30CA016672 (1)